| (210) | Number of the EPO application | 17711475 |
| (220) | Filing date of the EPO application | 2017.03.02 |
| (80) | EPO patent specification publication (B) | EPB nr. 18/2021, 2021.05.05 |
| (110) | EPO patent number | 3423105 |
| (11) | Number of the document | MD 3423105 T2 |
| (21) | Number of the application | e 2019 0061 |
| (71) | Name(s) of applicant(s), code of the country | Eisai R&D Management Co., Ltd., JP; |
| (72) | Name(s) of inventor(s), code of the country | ALBONE Earl F., US;
CHENG Xin, US;
CUSTAR Daniel W., US;
FURUUCHI Keiji, US;
LI Jing, US;
MAJUMDER Utpal, US;
UENAKA Toshimitsu, US; |
| (73) | Name(s) of owner(s), code of the country | EISAI R&D Management Co. Ltd., JP; |
| (54) | Title of the invention | Eribulin-based antibody-drug conjugates and methods of use |
| (13) | Kind-of-document code | T2 |
| (51) | International Patent Classification | A61K 47/68 (2017.01.01) |
| (19) | Country | JP |
| (41) | Date of publication of the application | 2019.02.28 |
| (49) | Date of publication of the translation of the validated European patent specification | 2021.10.31 |
| (30) | Priority | 201662302562 P, 2016.03.02, US |
| (74) | Patent attorney | (Procedură) CORCODEL Angela, Bd. Ştefan cel Mare nr. 134, Chişinău, Republica Moldova |
| (86) | International application | PCT/US2017/020529, 2017.03.02 |
| (87) | International publication | WO 2017/151979, 2017.09.08 |